Abstract-To induce crescentic-type anti-glomerular basement membrane (anti GBM) nephritis, male Sprague-Dawley rats were immunized with rabbit -(-globulin in Freund's complete adjuvant following i.v. injection of anti-GBM serum. At the same time, original type anti-GBM nephritis was induced in other rats by anti-GBM serum only. The animals with crescentic-type anti-GBM nephritis showed sig nificantly higher platelet aggregabil.ity than that in rats with original-type anti-GBM nephritis at days 5, 10 and 40 after anti-GBM serum administration, respectively. To estimate the antinephritic effect of OKY-046, a thromboxane A synthetase inhibitor, it was given orally to rats at doses of 0.5, 2.5 or 20 mg/kg for 39 days after anti-GBM serum. OKY-046 (20 mg/kg) significantly inhibited the increase in both urinary protein and plasma cholesterol levels (40% and 35% vs. control, respec tively). Moreover, when examined by light microscopy, this drug remarkably prevented histological involvement of the glomeruli. OKY-046 at 20 mg/kg had suppressed the hyperaggregability of platelets by 77% by day 40 as compared with the control, but doses of 0.5 and 2.5 mg/kg did not. It is concluded from these data that OKY-046 has beneficial effects on crescentic-type anti-GBM nephritis and may act through inhibition of not only platelet TxA2 but also glomerular TxA2 in its action to prevent histological alterations.
We have investigated antinephritic drugs by using experimental glomerulonephritis, especially anti-glomerular basement mem brane (GBM) nephritis in rats. The patho genesis of this model of nephritis has been widely studied for over two decades, and it has been suggested that a coagulant system could be implicated in the process of nephritis development (1) (2) (3) (4) (5) (6) . The antinephritic effects of anti-coagulant drugs, warfarin (7) and heparin (3, 8, 9) , on anti-GBM nephritis were evaluated. Recently, much attention has been focused on anti-platelet drugs as anti nephritic drugs since it has been demon strated that dipyridamole is experimentally and clinically effective against glomerulo nephrits (10) (11) (12) . Furthermore, in response to many vasoconstrictors such as angiotensin II, vasopreesin, histamine and epinephrine (13, 14) , cultures glomeruli and cultured me sangial cells can produce prostaglandins and thromboxane A2 (TxA2) that are secreted into the medium. Additionally, there is much evidence indicating that glomeruli obtained from rats suffering from various types of glomerulonephritis ehnance the production of prostaglandins and TxA2 (15) . TxA2 is a potent inducer of platelet aggregation and a vasoconstrictor (16, 17) . Thus, it is very likely that TxA2 derived from platelets or the mesangium can be attributed to the develop ment of glomerulonephritis. Therefore, many investigators have studied the antinephritic effects of thromboxane A synthetase inhib itors (18) (19) (20) . We also have reported that Y-19018, a thromboxane A synthetase inhib itor, inhibits the development of crescentic type anti-GBM nephritis in rats (21) . How ever, the antinephritic effect of thromboxane A synthetase inhibitors has been con troversial.
In this study we 1) studied the time course of platelet aggregability in original and crescentic-type anti-GBM glomerulonephritis and 2) examined the antinephritic effect of another thromboxane A synthetase inhibitor, OKY-046, using crescentic-type anti-GBM nephritis.
Materials and Methods 1. Animals: Male Sprague-Dawley rats (Sizuoka Jikken Doubutsu Kyodo Kumiai) weighing 160-170 g were used in all ex periments.
2. Experimental nephritis: Rats were in travenously injected with 0.56 or I ml/rat of anti-GBM serum, which was produced in rabbits as reported (5) . Original-type anti GBM nephritis was induced by the injection of anti-GBM serum alone. On the other hand, crescentic-type anti-GBM nephritis was induced by the injection of anti-GBM serum followed by subcutaneous immunization with 6.5 mg of rabbit r-globulin in 0.25 ml of Freund's complete adjuvant, injected into the hind foot pads the next day.
3. Determination of platelet aggregability in whole blood (22) : To determine the changes in platelet aggregability in nephritic rats after the injection of anti-GBM serum, 2.25 ml of blood was gently drawn, prevenously, from the renal vein into a disposable syringe con taining 0.25 ml of 3.18% sodium citrate and then left for one hour at room temperature. We collected the blood from the renal vein since we thought that the renal blood can give us information about the glomeruli under nephritis.
We determined platelet aggre gability in both original and crescentic-types of anti-GBM nephritis on days 1, 3, 5, 10, 20, 30 and 40.
Platelet aggregability was measured by whole blood aggregometer, model C-560 (Crono-log Co.). Five hundred microliters of blood were added to 495 ul of 0.9% saline in a small aggregometer cuvette. This cuvette was maintained at 37 °C by a heated block and the contents were stirred with a flea magnet. An electrode was inserted into the sample. (Fig. 1) . OKY-046 was dissolved in distilled water. Animals received this orally in a volume of 1 ml/100 g of body weight. OKY-046 was administered daily at a dose of 0.5, 2.5 or 20 mg/kg (p.o.) for 39 days after the injection of rabbit r-globulin.
Ujiie et al. (23) demon strated that serum TxB2 level fell to nearly 0 in the whole blood of rabbits fed on high lipid diets by the oral administration of OKY 046 at 10 or 100 mg/kg, twice a day.
In addition to the drug-treated group, non treated nephritic (control) and normal groups were used in both experiments.
5. General condition, body weight and urine volume: General condition was ob served, and body weight and urine volume were determined during the experiment.
6. Urine, blood and kidney: Twenty-four hour urine samples were obtained on days 0, 5, 9, 29 and 39 after the injection of anti -GBM serum. Blood samples were obtained from the tail vein on days 7, 15, 25 and 36 after the injection of anti-GBM serum. In addition, on day 40, each animal was an esthetized with sodium pentobarbital (30 mg/kg) after the last collection of a urine sample, and a blood sample was collected from the renal vein to determine platelet aggregability.
The kidneys were then im mediately isolated and used in histopatholo gical preparations.
7. Determination of biochemical param eters in urine and plasma:
The protein content in urine was determined by the method of Kingsbury et al. (24) and ex pressed as mg per day. Cholesterol content in plasma was determined with a commercial assay kit (Determina TC-5, Kyouwa Medix Co., Ltd.) (25) . Urea nitrogen content in plasma was determined by the urease indophenol spectrophotometry assay (26) . Both cholesterol and urea nitrogen contents were reported as mg per 1 dl of plasma.
8. Light microscopic studies: The kidney was dehydrated stepwise and fixed by im mersing the tissue into progressively higher concentrations of alcohol. Thereafter, the tissue was embedded in paraffin and cut into 3-/im thick sections. The sections were stained with hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome. Fifty glomeruli per section were observed under a light microscope for evaluating crescent for mation, adhesion to Bowman's capsule of the capillary wall and fibrinoid necrosis. Each histopathological parameter was calculated as an index for crescent formation, for adhesion to Bowman's capsule of the capil lary wall and for fibrinoid necrosis as re ported previously (27) . Each histological parameter was graded normal (0 point), mild (1 point), moderate (2 point) and severe (3 point) according to the extent of alteration. The number of glomeruli corresponding to each score was represented as no, n, , n2 and n3. Indexes for crescent formation (CI), adhesion to Bowman's capsule of the capil lary wall (Al) or for fibrinoid degeneration (FI) were calculated as follows: CI, Al or FI=(1 xn,)+(2Xn2)+(3xn3).
9. Statistical analysis: All data were pre sented as the mean±S.D., and the signifi cance of difference was determined by analysis of variance, Student's t-test or Mann Whitney's U-test. Inhibitory percentage was calculated as follows: inhibitory percentage (%) Control-Test drug X 100 C ontrol-Normal Results 1. Changes in platelet aggregability after in jection of anti-GBM serum (Fig. 2) Platelet aggregability had significantly in creased since day 5 in nephritic rats com pared to that in normal rats. Although on days 30 and 40, platelets from rats with original type anti-GBM nephritis showed only slightly higher aggregability than that in normal rats, the platelet aggregability in rats with crescen tic-type anti-GBM nephritis was significantly higher than that in normal rats. In the rats with crescentic-type anti-GBM nephritis through out the experimental period, and especially on days 5, 20 and 40, this difference was notable.
General condition
No rats given OKY-046 died during the experiments.
A similar amount of rat chow was consumed by both the control and OKY 046 groups. In addition, none of the rats given OKY-046 exhibited any abnormal behavior or diarrhea. 3. Body weight and urine volume (Table 1) The control and OKY-046 groups showed lower body weights than that of the normal group on days 20 and 40. Both control and OKY-046-treated rats showed a similar course of weight gain. The rats injected with anti-GBM serum excreted less urine than normal rats on days 1 and 20. However, on day 20 OKY-046 administer rats showed an increase in urine volume, which was pre viously at a nearly normal level, in com parison with the control rats. The difference in urine volume among them was negligible at the end of the experiment.
Effect of OKY-046 on biochemical param eters in urine and plasma
Urinary protein (Fig. 3) : Normal rats ex creted about 10 mg/day of protein into urine throughout the experimental period. Control rats revealed proteinuria that contained from 100 to 150 mg/day of protein on day 1 after the injection of anti-GBM serum. Thereafter, proteinuria remained at a level of about 150 mg/day of protein. On the other hand, 20 mg/ kg of OKY-046 resulted in a urinary protein level of about 40% less than that in the control rats on days 20 and 30 which was a signifi cant difference. The rats administered 0.5 or 2.5 mg/kg of OKY-046, however, displayed proteinuria at a level similar to that of the control rats.
Plasma cholesterol ( Table 2 ): The content of cholesterol in the control rats increased to a level of about 150 mg/dl day 8 after the in jection of anti-GBM serum. OKY-046 (20 mg/kg) significantly decreased plasma cholesterol by about 75% of that of the control group by day 22. However, 0.5 and 2.5 mg/ kg of OKY-046 no effect on the serum cholesterol level.
Plasma urea nitrogen (Table  3 ): The control rats had a slightly higher level of plasma urea nitrogen than the normal rats, and this elevation was significant. The rats administered 20 mg/kg of OKY-046, but not 0.5 and 2.5 mg/kg of OKY-046, revealed less urea nitrogen content in comparison with that of the control rats at the end of the experiment. 5. Effect of OKY-046 on platelet aggre gability (Fig. 4) While platelet aggregability in response to collagen was 8.9±1.8Q in the normal rats, the A: OKY-046, 20 mg/kg/ day, p.o. ** indicates a significant difference from the control at P<0.01. 
